Synlogic (NASDAQ:SYBX – Get Free Report) is anticipated to release its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to post earnings of ($5.80) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.
Synlogic Stock Performance
NASDAQ SYBX opened at $1.00 on Wednesday. The company has a market cap of $12.25 million, a PE ratio of -3.85 and a beta of 0.61. The firm’s 50 day moving average price is $1.12 and its 200-day moving average price is $0.83. Synlogic has a 52-week low of $0.54 and a 52-week high of $1.86.
About Synlogic
Synlogic, Inc was a clinical-stage biopharmaceutical company focused on developing medicines based on synthetic biology. Its platform used genetically engineered probiotic bacteria, known as Synthetic Biotics, designed to carry out specific therapeutic functions inside the gastrointestinal tract.
The company’s research programs targeted metabolic and gastrointestinal disorders. Its leading candidates included SYNB1934, an investigational treatment intended to help break down phenylalanine in people with phenylketonuria, and SYNB8802, which was designed to consume oxalate in the gut for the potential treatment of enteric hyperoxaluria.
Recommended Stories
- Five stocks we like better than Synlogic
- Meta’s $100 Billion AI Financing Plan Has a Catch for Existing Shareholders
- Tower Semiconductor’s Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?
- Shopify’s Small Q3 Miss Triggered a Big Sell-Off: What’s Next?
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.
